SOCRA CCRP Exam Dumps

Phase classification is based on study objectives, not just subject numbers.

Phase I: Focuses on safety, pharmacokinetics, dose-ranging, usually in healthy volunteers or small patient groups.

Phase II: Evaluates effectiveness in patients with the condition and monitors common short-term side effects.

Phase III: Confirms effectiveness in larger populations, compares to standard therapy, gathers more safety data.

Phase IV: Post-marketing studies exploring new indications, long-term safety, or special populations.

The given study aims to evaluate effectiveness and common short-term side effects in 30 arthritis patients, which clearly aligns with Phase II objectives. It is not exploratory safety (Phase I), not confirmatory comparative (Phase III), nor post-marketing (Phase IV).

Thus, the correct answer is B (Phase II).

FDA Guidance: The IND Application --- 312.21 (Phases of an investigation).

ICH E8(R1), General Considerations for Clinical Studies.

Handling of investigational product (IP), including returns, is governed by sponsor's written procedures.

ICH E6(R2) 4.6.3: ''The investigator/institution should maintain records of the product's delivery, the inventory, the use by each subject, and the return to the sponsor or alternative disposition.''

ICH E6(R2) 5.13.3: ''The sponsor should ensure that written procedures include instructions for... the return or alternative disposition of unused product(s).''

The IB (A) describes pharmacology and safety, not IP logistics. CRO agreements (C) cover contractual duties, not product return processes. Local pharmacy policies (D) may apply operationally but do not override sponsor-required procedures.

Thus, the correct answer is B (The sponsor's written procedures).

ICH E6(R2), 4.6.3 (Investigator product accountability).

ICH E6(R2), 5.13.3 (Sponsor product return procedures).

The protocol governs all trial conduct, including whether subjects should be replaced when they withdraw.

ICH E6(R2) 6.0: The protocol must contain ''detailed information on trial design, methodology, statistical considerations, and the organization of the trial.''

ICH E6(R2) 6.9.2: The section on ''Subject withdrawal or discontinuation'' specifies ''whether and under what conditions subjects may be replaced.''

Other documents serve different functions: the DSM plan (A) manages safety oversight, the IB (C) summarizes product background, and the consent form (D) explains subject rights but does not guide study conduct. Only the protocol provides the operational answer regarding replacement.

Thus, the correct answer is B (The protocol).

ICH E6(R2), 6.0 (Protocol content).

ICH E6(R2), 6.9.2 (Subject withdrawal/discontinuation).

Upon study closure, investigators must maintain documentation that allows subject data to be linked back if necessary. The Subject Identification Code List is a key essential document for ensuring traceability while maintaining confidentiality.

ICH E6(R2) 8.3.21: ''Subject Identification Code List --- A list of all subjects randomized to trial numbers, allowing investigator to identify each subject in case follow-up is required. This list should be kept in a confidential manner and retained for the maximum retention period.''

ICH E6(R2) 8.4: Essential documents for investigators include items needed for subject identification, protocol compliance, and trial closure.

Other listed documents (randomization list, monitoring report, audit certificate) are maintained by the sponsor, not the investigator. The subject code list ensures that in the event of a safety issue, regulatory authority queries, or subject withdrawal, the investigator can trace back records.

Thus, the correct answer is B (Completed Subject Identification Code List).

ICH E6(R2), 8.3.21 (Essential documents: Subject identification code list).

ICH E6(R2), 8.4 (Essential documents for trial closure).

21 CFR 11.100(a): Requires that electronic signatures be ''unique to one individual and shall not be reused or reassigned to anyone else.''

This ensures accountability and audit trail integrity.